No Data
No Data
fusen pharm (01652.HK) appointed Yang Yukang as the company secretary
Glory news on September 30th: fusen pharm (01652.HK) announced that Mr. Wang Dimin has resigned from the company as company secretary and authorized representative, effective from September 30, 2024. After Mr. Wang's resignation, the board of directors is pleased to announce that Mr. Yang Yukang has been appointed as the company secretary and authorized representative, effective from September 30, 2024.
FUSEN PHARM: Interim Report 2024
Fusen Pharmaceutical's Unit's Flu Drug Gets China Nod for Clinical Trials
Fusen Pharm (01652.HK): Application for clinical trial of type 1.1 traditional Chinese medicine innovative drug "SY617" approved.
On September 19th, Fusen Pharm (01652.HK) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has obtained approval from the China National Medical Products Administration for the clinical trial of "SY617" (Approval Number: 2024LP02103). SY617 is primarily used for the treatment of epidemic influenza with the pattern of wind-heat and dampness in traditional Chinese medicine, with symptoms such as fever, heaviness of the head, sore throat, aversion to wind, cough, body aches, chest tightness, epigastric fullness, red tongue with white or greasy coating, and slippery or rapid or floating pulse. According to data from Mi Nei, as of
Express News | Fusen Pharmaceutical - Clinical Trial for ``Sy617'' Approved by Nmpa
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
No Data
No Data